Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clene (CLNN)
NASDAQ:CLNN
Holding CLNN?
Track your performance easily
CLNN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.82 - $13.21
Previous Close$5.02
Volume103.14K
Average Volume (3M)125.88K
Market Cap
$33.45M
Enterprise Value$38.15M
Total Cash (Recent Filing)$21.68M
Total Debt (Recent Filing)$27.35M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Nov 05, 2024EPS Estimate
-$1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding6,470,067
10 Day Avg. Volume97,181
30 Day Avg. Volume125,875
Standard Deviation0.29
R-Squared0.02
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-62.75
Price to Sales (P/S)77.44
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue86.31
Enterprise Value/Gross Profit71.57
Enterprise Value/Ebitda-1.61
Forecast
1Y Price Target
$51.60Price Target Upside898.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Clene News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyNew biomarker and survival data support the clinical efficacy of CNM-Au8 in ALS patients.
Preclinical DataPreclinical data shows CNM-Au8 treatment improves mitochondrial respiration and supports neuroprotection in Rett astrocytes.
Regulatory DevelopmentThe FDA granted a meeting with senior leadership to discuss CNM-Au8's data package and potential filing.
Bears Say
Biomarker InsufficiencyThe FDA had said the initial findings on neurofilament light chain (NfL) biomarker results were insufficient to support a filing for accelerated approval at the time.
FDA RejectionThe FDA rejected CNM-Au8’s current data package as being sufficient for a filing for an Accelerated Approval for treating amyotrophic lateral sclerosis (ALS).
Financial PerformanceClene likely needs to raise capital to continue operations, but the outcome of the FDA meeting and a potential filing are seen as catalysts to drive shares and financing.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLNN FAQ
What was Clene’s price range in the past 12 months?
Clene lowest stock price was $3.82 and its highest was $13.21 in the past 12 months.
What is Clene’s market cap?
Currently, no data Available
When is Clene’s upcoming earnings report date?
Clene’s upcoming earnings report date is Nov 05, 2024 which is in 46 days.
How were Clene’s earnings last quarter?
Clene released its earnings results on Aug 07, 2024. The company reported -$1.06 earnings per share for the quarter, beating the consensus estimate of -$1.508 by $0.448.
Is Clene overvalued?
According to Wall Street analysts Clene’s price is currently Undervalued.
Does Clene pay dividends?
Clene does not currently pay dividends.
What is Clene’s EPS estimate?
Clene’s EPS estimate is -$1.35.
How many shares outstanding does Clene have?
Clene has 6,470,067 shares outstanding.
What happened to Clene’s price movement after its last earnings report?
Clene reported an EPS of -$1.06 in its last earnings report, beating expectations of -$1.508. Following the earnings report the stock price went down -23.469%.
Which hedge fund is a major shareholder of Clene?
Currently, no hedge funds are holding shares in CLNN
---
Clene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.60 (898.07% Upside)
$51.60 (898.07% Upside)
Blogger Sentiment
Bullish
CLNN Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.52%
12-Months-Change
Fundamentals
Return on Equity
-289.66%
Trailing 12-Months
Asset Growth
-40.56%
Trailing 12-Months
Company Description
Clene
Clene is a clinical-stage biopharma company focused on developing and commercializing nanotherapeutics for the treatment of neurodegenerative disease.
---
CLNN Stock 12 Month Forecast
Average Price Target
$51.60
▲(898.07% Upside)
Technical Analysis
Annovis Bio
―
Anavex Life Sciences
―
Brainstorm Cell Therapeutics
―
Cyclacel Pharmaceuticals
―
Best Analysts Covering CLNN
1 Year
1 Year Success Rate
1/16 ratings generated profit
1 Year Average Return
-39.58%
reiterated a buy rating 4 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 6.25% of your transactions generating a profit, with an average return of -39.58% per trade.
---